The UroLift ATC System was cleared by the
The new UroLift ATC System delivers the same proven UroLift implant through an enhanced delivery device tip. It features tissue control wings that hold tissue during manipulation, enabling the urologist to mobilize obstructive tissue and pin it to the side to enhance visualization and open up the blockage caused by the enlarged prostate. The tissue control wings are strategically shaped to optimize the view of obstructing tissue. The UroLift ATC System also includes a needle location marker with laser-etched markings that can aid with targeting accuracy for predictable implant placement.
“We are encouraged by early positive responses from urologists to the UroLift ATC System. Urologists are reporting high satisfaction with its ease of use and indicating their willingness to adopt the new device in their practices to treat patients with challenging anatomies, including obstructive median lobe and large lateral lobes,” said
“My experience with the UroLift ATC System has been overwhelmingly positive,” said
The UroLift System has consistently achieved statistically significant results in patients with an obstructive median lobe; the new UroLift ATC System will make it easier to handle the more complex anatomy of these patients. Data published from the MedLift Study showed that patients who were treated for obstructive median lobe with the standard UroLift System experienced significant improvements in IPSS (International Prostate Symptom Score), Qmax (peak flow rate), and QoL (quality of life) scores:1
- Mean IPSS improved from baseline by at least 13.5 points (p<0.0001).
- Quality of life and BPH Impact Index scores were improved (>60% and >70%, respectively at 3, 6, and 12 months, p<0.0001).
- Mean Qmax improvement ranged from 90-129% (p<0.0001). At one month, 80% of men (95% CI 66- 89%) reported being ‘much’ or ‘very much better,’ and 89% (95% CI 76-95%) would recommend the procedure.
- Bother due to ejaculatory function improved rapidly and remained modestly improved at one year (p=0.001). No patient reported de novo sustained ejaculatory or erectile dysfunction.
About the UroLift® System
The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without cutting, heating, or removing prostate tissue. The UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal study.2-5 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.2 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. As with any medical procedure, individual results may vary. Consult the Instructions for Use (IFU) for more information. The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the
About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving sexual function.**2,4,5 Learn more at www.NeoTract.com.
About
+Dr. Steven Gange is a paid consultant of
*Management estimate based on product sales and average units per procedure
**No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T pivotal study
Contacts:
For
Treasurer and Vice President, Investor Relations
Media:
nicole@healthandcommerce.com
1. Rukstalis et. al, Prostate Cancer and Prostatic Diseases 2018 MedLift Study
2. Roehrborn, J Urology 2013 LIFT Study
3. Roehrborn, Can
4. AUA BPH Guidelines 2003, 2020
5. McVary, J Sex Med 2016
MAC01742-01 Rev A
Source:
2020 GlobeNewswire, Inc., source